Myopericarditis After BNT162b2 mRNA Vaccination With Incidental Intramyocardial Bridging.
bnt162b2
bnt162b2 mrna vaccine
coronavirus disease 2019
covid-19
covid-19 vaccine
intramyocardial bridging
mrna vaccination
myocarditis
pericarditis
pfizer-biontech
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
31
01
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Myocarditis and pericarditis are inflammatory conditions affecting the myocardium and pericardium, respectively. They are caused by infectious and non-infectious conditions, including autoimmune disorders, drugs, and toxins. Vaccine-induced myocarditis has been reported with viral vaccines, including influenza and smallpox. The BNT162b2 mRNA vaccine (Pfizer-BioNTech) has shown great efficacy against symptomatic, severe coronavirus disease 2019 (COVID-19), hospital admissions, and deaths. The US FDA issued an emergency use authorization for the Pfizer-BioNTech COVID-19 mRNA vaccine for the prevention of COVID-19 in individuals ≥ five years. However, concerns were raised after reports of new cases of myocarditis following mRNA COVID-19 vaccines, especially among adolescents and young adults. Most cases developed symptoms after receiving the second dose. Here, we present a case of a previously healthy 34-year-old male who developed sudden and severe chest pain a week after the second dose of the Pfizer-BioNTech COVID-19 mRNA vaccine. Cardiac catheterization showed no angiographically obstructive coronary artery disease but it revealed intramyocardial bridging. This case report demonstrates that the mRNA COVID-19 vaccine can be associated with acute myopericarditis and the clinical presentation can mimic acute coronary syndrome. Despite that, acute myopericarditis associated with the mRNA COVID-19 vaccine is usually mild and can be managed conservatively. Incidental findings such as intramyocardial bridging should not exclude the diagnosis of myocarditis and should be carefully evaluated. COVID-19 infection has high mortality and morbidity even in young individuals, and all different COVID-19 vaccines were found effective in the prevention of severe COVID-19 infection and in decreasing COVID-19 mortality.
Identifiants
pubmed: 36874673
doi: 10.7759/cureus.34452
pmc: PMC9982053
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e34452Informations de copyright
Copyright © 2023, Elghazal et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nat Med. 2022 Feb;28(2):410-422
pubmed: 34907393
BMC Cardiovasc Disord. 2021 Apr 14;21(1):178
pubmed: 33853525
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
J Clin Med. 2021 Dec 15;10(24):
pubmed: 34945172
Circulation. 2021 Aug 10;144(6):506-508
pubmed: 34133884
MMWR Morb Mortal Wkly Rep. 2021 Jul 09;70(27):977-982
pubmed: 34237049
Clin Med (Lond). 2021 Sep;21(5):e505-e510
pubmed: 34507935
Heart Fail Rev. 2022 Nov;27(6):2033-2043
pubmed: 35449353
Z Kardiol. 1985 Dec;74(12):700-5
pubmed: 4096063
J Korean Med Sci. 2021 Oct 18;36(40):e286
pubmed: 34664804
Tokai J Exp Clin Med. 2000 Jun;25(2):57-60
pubmed: 11127508
JAMA Netw Open. 2022 Jun 1;5(6):e2218505
pubmed: 35749115
Annu Rev Pathol. 2008;3:127-55
pubmed: 18039131
BMJ. 2021 Dec 16;375:e068665
pubmed: 34916207
Circulation. 2018 Sep 11;138(11):1088-1099
pubmed: 29764898
Vaccine. 2022 Jul 30;40(32):4663-4671
pubmed: 35750537
J Invasive Cardiol. 2015 Nov;27(11):521-8
pubmed: 25999138
Eur Cardiol. 2021 Mar 03;16:e05
pubmed: 33737959